The development programme for the oncology drug encompasses Piramal’s resources from India, North America, and Europe
Image as seen on Piramal website
Global CDMO Piramal Pharma Services has announced a partnership with BerGenBio. The contractor will work with BerGenBio on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML).
Bemcentinib is an AXL protein inhibitor that was recently designated as a Fast Track drug by the US Food and Drug Administration (FDA), as there are currently no marketed drugs specifically approved for relapsed AML patients.
The bemcentinib development programme encompasses a fully integrated portfolio of Piramal’s resources that includes intermediates sourced from India, pilot process development and API validation in North America and formulation development in Europe.
As part of the partnership agreement, PPS is also expected to provide commercial manufacturing of the final drug product.
Richard Godfrey, CEO of BerGenBio, said: "Outsourcing of development and manufacturing services is a requirement for us, and we were rigorous in our due diligence of potential partners.”